Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy

No AccessJournal of UrologyAdult Urology1 Mar 2013Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy LaMont J. Barlow, James M. McKiernan, and Mitchell C. Benson LaMont J. BarlowLaMont J. Barlow , James M. McKiernanJames M. McKiernan , and Mitchell C. BensonMitchell C. Benson View All Author Informationhttps://doi.org/10.1016/j.juro.2012.10.068AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Docetaxel is a safe agent for intravesical therapy. Adding monthly maintenance treatments can extend response durability. We report our cumulative experience with intravesical docetaxel in a larger cohort with extended followup. Materials and Methods: A total of 54 patients received salvage intravesical docetaxel for bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer between 2003 and 2012, including 18 treated during the original phase I trial. All patients received 6 weekly instillations of intravesical docetaxel. After the phase I trial, those with a complete response to induction treatment were offered single dose monthly maintenance treatments for a total of up to 12 months of docetaxel therapy. Recurrence was defined as positive biopsy or urine cytology. Recurrence-free, disease specific and overall survival was determined by Kaplan-Meier analysis. Results: Median followup was 39.1 months. Of the 54 patients 32 (59%) had a complete initial response after induction therapy, including 18 who received additional monthly maintenance treatments. Median time to recurrence in initial responders treated with vs without docetaxel maintenance was 39.3 vs 19.0 months. One and 3-year recurrence-free survival rates for the entire cohort were 40% and 25%, respectively. Of the 54 patients 17 (24%) underwent radical cystectomy at a median of 24 months of followup. Five-year disease specific and overall survival rates were 85% and 71%, respectively. Conclusions: Intravesical docetaxel appears to be a promising agent with significant efficacy and durability for bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. Adding maintenance treatments may increase the duration of recurrence-free survival. References 1 : The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder: Bladder Consensus Conference Committee. Am J Surg Pathol1998; 22: 1435. Google Scholar 2 : Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol1976; 116: 180. Link, Google Scholar 3 : Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol1982; 128: 27. Link, Google Scholar 4 : Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS): American Urological Association. J Urol1999; 162: 1697. Link, Google Scholar 5 : Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol2005; 174: 86. Link, Google Scholar 6 : A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?. J Urol1991; 146: 32. Link, Google Scholar 7 : Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol1997; 80: 762. Google Scholar 8 : Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol2002; 168: 1964. Link, Google Scholar 9 : Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology2004; 63: 682. Google Scholar 10 : Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol1987; 137: 220. Link, Google Scholar 11 : Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol2006; 24: 3075. Google Scholar 12 : Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer1998; 78: 1342. Google Scholar 13 : Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol1999; 17: 2341. Google Scholar 14 : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med2004; 351: 1502. Google Scholar 15 : New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol2002; 20: 158. Google Scholar 16 : The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol2009; 27: 331. Google Scholar 17 : Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol2000; 163: 1124. Link, Google Scholar 18 : Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol2007; 52: 1123. Google Scholar 19 : Nonparametric estimation of incomplete observations. J Am Stat Assoc1958; 53: 457. Google Scholar 20 : Non-muscle-invasive bladder cancer (Ta, T1, and CIS). In: . Philadelphia: Saunders2006: 2447. Google Scholar 21 : Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol1992; 147: 1020. Link, Google Scholar 22 : Assessment of perioperative psychological distress in patients undergoing radical cystectomy for bladder cancer. J Urol2004; 172: 1814. Link, Google Scholar 23 : Intravesical therapy for superficial cancer: need for more options. J Clin Oncol2002; 20: 3185. Google Scholar 24 : Effect of ileal conduit on patients' activities following radical cystectomy. Urology1991; 37: 33. Google Scholar 25 : Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol1997; 40: 285. Google Scholar 26 : Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment: European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol1995; 153: 934. Link, Google Scholar 27 : A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guerin therapy. BJU Int2009; 104: 1098. Google Scholar 28 : Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol2001; 166: 1296. Link, Google Scholar Department of Urology, Columbia University Medical Center, New York Presbyterian Hospital, New York, New York© 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byNazmifar M, Williams C, Naser-Tavakolian A, Heard J, Rosser C, Theodorescu D and Ahdoot M (2022) Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin FailureJournal of Urology, VOL. 209, NO. 1, (32-48), Online publication date: 1-Jan-2023.McElree I, Steinberg R, Martin A, Richards J, Mott S, Gellhaus P, Nepple K, O'Donnell M and Packiam V (2022) Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder CancerJournal of Urology, VOL. 208, NO. 3, (589-599), Online publication date: 1-Sep-2022.Steinberg R, Thomas L, Brooks N, Mott S, Vitale A, Crump T, Rao M, Daniels M, Wang J, Nagaraju S, DeWolf W, Lamm D, Kates M, Hyndman M, Kamat A, Bivalacqua T, Nepple K and O'Donnell M (2019) Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 203, NO. 5, (902-909), Online publication date: 1-May-2020.Chang S (2019) Re: Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder CancerJournal of Urology, VOL. 201, NO. 5, (857-858), Online publication date: 1-May-2019.Chang S (2019) Re: Long-Term Survival Outcomes with Intravesical Nanoparticle Albumin-Bound Paclitaxel for Recurrent Non-Muscle-Invasive Bladder Cancer after Previous bacillus Calmette-Guérin TherapyJournal of Urology, VOL. 201, NO. 4, (665-665), Online publication date: 1-Apr-2019.McKiernan J, Holder D, Ghandour R, Barlow L, Ahn J, Kates M, Badalato G, Roychoudhury A, Decastro G and Benson M (2014) Phase II Trial of Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment of Nonmuscle Invasive Urothelial Carcinoma of the Bladder after bacillus Calmette-Guérin Treatment FailureJournal of Urology, VOL. 192, NO. 6, (1633-1638), Online publication date: 1-Dec-2014. Volume 189Issue 3March 2013Page: 834-839 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.Keywordsintravesicalurinary bladder neoplasmsadministrationdocetaxelurinary bladderinvestigationaltherapiesMetrics Author Information LaMont J. Barlow More articles by this author James M. McKiernan More articles by this author Mitchell C. Benson More articles by this author Expand All Advertisement PDF downloadLoading ...